Lynda E. Rosenfeld

Dr. Lynda E. Rosenfeld


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2014 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
LRLynda E. Rosenfeld
Lynda E. Rosenfeld
APAmisha S. Patel
Amisha S. Patel
VAVivek B. Ajmani
Vivek B. Ajmani
RHReece W. Holbrook
Reece W. Holbrook
TBTrina A. Brand
Trina A. Brand

4 May 2004 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
AKAshok K. Koul
Ashok K. Koul
SKSeth Keller
Seth Keller
JCJude F. Clancy
Jude F. Clancy
RLRachel Lampert
Rachel Lampert
WBWilliam P. Batsford
William P. Batsford
LRLynda E. Rosenfeld
Lynda E. Rosenfeld

1 September 2020 in Heart Rhythm
Verified
Journal Article
Closed access
SJShashank Jain
Shashank Jain
VWVirginia Workman
Virginia Workman
RGRaj Ganeshan
Raj Ganeshan
EOEdinrin R. Obasare
Edinrin R. Obasare
ABAlicia Burr
Alicia Burr
LRLynda E. Rosenfeld
Lynda E. Rosenfeld

16 February 2021 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
LRLynda E. Rosenfeld
Lynda E. Rosenfeld
MCMina K. Chung
Mina K. Chung
CHClifford V. Harding
Clifford V. Harding
PSPaolo Spagnolo
Paolo Spagnolo
JGJohan Grunewald
Johan Grunewald
JEJerry D. Estep
Jerry D. Estep
Cardiac sarcoidosis is a component of an often multiorgan granulomatous disease of still uncertain cause. It is being recognized with increasing frequency, mainly as the result of heightened awareness and new diagnostic tests, specifically cardiac magnetic resonance imaging and 18 F-fluorodeoxyglucose positron emission tomography scans. The purpose of this case-based review is to highlight the potentially life-saving importance of making the early diagnosis of cardiac sarcoidosis using these new tools and to provide a framework for the optimal care of patients with this disease. We will review disease mechanisms as currently understood, associated arrhythmias including conduction abnormalities, and atrial and ventricular tachyarrhythmias, guideline-directed diagnostic criteria, screening of patients with extracardiac sarcoidosis, and the use of pacemakers and defibrillators in this setting. Treatment options, including those related to heart failure, and those which may help clarify disease mechanisms are included.

28 August 2008 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
JLJeffrey J. Luebbert
Jeffrey J. Luebbert
FLForrester A. Lee
Forrester A. Lee
LRLynda E. Rosenfeld
Lynda E. Rosenfeld

29 May 2023 in Arrhythmia and Electrophysiology Review
Verified
Journal Article
Open access
MAManyoo Agarwal
Manyoo Agarwal
ASAadhavi Sridharan
Aadhavi Sridharan
RPRhea C Pimentel
Rhea C Pimentel
SMSteven M Markowitz
Steven M Markowitz
LRLynda E. Rosenfeld
Lynda E. Rosenfeld
EYEric H Yang
Eric H Yang
Cardiovascular disease and cancer are the leading causes of morbidity and mortality in the US. Despite the significant progress made in cancer treatment leading to improved prognosis and survival, ventricular arrhythmias (VA) remain a known cardiovascular complication either exacerbated or induced by the direct and indirect effects of both traditional and novel cancer treatments. Although interruption of cancer treatment because of VA is rarely required, knowledge surrounding this issue is essential for optimising the overall care of patients with cancer. The mechanisms of cancer-therapeutic-induced VA are poorly understood. This review will discuss the ventricular conduction (QRS) and repolarisation abnormalities (QTc prolongation), and VAs associated with cancer therapies, as well as existing strategies for the identification, prevention and management of cancer-treatment-induced VAs.